Adalvo announces the successful earlier-than-expected DCP approval for Empagliflozin 10mg and 25mg film-coated tablets.
Our product has been developed based on the reference brand Jardiance film-coated tablets, which are indicated for the treatment of type 2 diabetes mellitus and for symptomatic chronic heart failure and chronic kidney disease in adults.
The brand sold approximately $18.8bn globally in 2023, with significant growth potential and a global 3Y CAGR of +24%, according to IQVIA.
This successful milestone highlights Adalvo's ability to develop difficult-to-make, high-value differentiated dossiers for our partners.
Adalvo has developed one of the broadest diabetes pipelines in the industry with an extensive range of therapeutic options. Our diverse portfolio includes small molecules and peptide-based treatments, encompassing both oral and parenteral formulations, from short to long-acting. This comprehensive approach makes diabetes care more manageable for patients worldwide.
There are no half-measures at Adalvo – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Partner Up Now!